Clinical Trials Browser

Not yet recruiting × Interventional × Angiogenesis Inhibitors × Clear all

NCT06475755 2024-06-26

Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06063070 2023-10-02

First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer

Phase 2 Not yet recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms